Cleveland Clinic European Society of Cardiology 2016 Symposium

Targeting Residual Cardiovascular Risk: Emerging Therapies and Novel Approaches

By Cleveland Clinic European Society of Cardiology 2016 Symposium
September 16, 2016
1 Comment
Login to view comments. Click here to Login

Related Content

AUTOPLAY
Houston Methodist DeBakey Heart and Vascular Center

Houston Heart Failure Summit

Fri, Feb 19, 2021
Didactic Presentations

21st Annual San Diego Heart Failure Symposium for Primary Care and Inter...

Fri, Jan 29, 2021
25:31
Novartis

The War on Heart Failure

Feat. E. Braunwald
14:44
26th Annual San Diego Heart Failure Symposium

Broadening Indications for the Use of Angiotensin Receptor Neprilysin In...

Feat. C. Yancy
14:16
Scott Solomon

Angiotensin Receptor Neprilysin Inhibition for Heart Failure

07:16
Novartis

The Importance of Physical Examination in Patients With Heart Failure

Feat. G. Ewald
88:01
Cardiac Contractility Modulation

Device Options for Treatment of HF - Finding the Fit Debate (Complete Vi...

Feat. V. Thohan, G. Tomassoni, R. Doshi, F. Abi-Samra, I. Rao
64:40
Cardiac Contractility Modulation

CCM® Therapy - Understanding CCM® and Identifying Patients - A Case Base...

Feat. A. Kaplan, H. Saltzman
17:22
Getinge

IABP case study in Advance Heart Failure

Feat. J. Estep
17:23
Northwestern Medicine: 8th Annual Cardiovascular Update

AF and Heart Failure: What’s the Risk? Is Ablation the Answer?

Feat. J. Piccini
10:32
Inova Heart and Vascular Institute 2019 Cardiovascular Symposium

Managing Heart Failure with Reduced Ejection Fraction in 2019

Feat. J. Teerlink
26:38
AACC American Association for Clinical Chemistry

Evaluation of Sex-Specific 99th Percentile URLs for hs-cTn Assays: Will ...

Feat. F. Apple
22:43
Mount Sinai Advanced Heart Symposium 2016

Chronic Heart Failure Update: Incorporating Sacubatril / Valsartan and I...

Feat. S. Pinney
07:57
Novartis

An Introduction to Heart Failure

Feat. J. Januzzi
19:25
Novartis

Biomarkers in Heart Failure

Feat. J. Januzzi
43:21
Novartis

Heart Failure from Bench to Bedside: The Role of Natriuretic Peptides

Feat. J. Burnett, J. Januzzi
25:40
Novartis

The Role of the Kidneys in Heart Failure Progression

Feat. J. Diez
15:56
Cardiology Fiesta 2018

Update on New Pharmacological Therapy for Heart Failure

Feat. B. Bozkurt
10:08
Novartis

Care Processes in the Hospitalized Patient with Heart Failure

Feat. G. Mentzer
22:09
The 8th Annual International Hawaii Symposium on Diagnostic and Therapeutic Modalities in Heart Failure

Managing Side Effects and Drug-Drug Interactions in Heart Failure Patients

19:50
Piedmont Heart Institute Napa Valley Cardiology Conference

Advanced Heart Failure: What Is It and When to Refer?

09:00
Novartis

Diagnostic and Monitoring Tools and Tests in Heart Failure

Feat. W. Abraham